There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MacroGenics (MGNX – Research Report), KalVista Pharmaceuticals (KALV – Research Report) and Oramed Pharmaceuticals (ORMP – Research Report) with bullish sentiments.
MacroGenics (MGNX)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on MacroGenics today and set a price target of $35.00. The company’s shares closed last Friday at $3.50, close to its 52-week low of $2.13.
According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on MacroGenics is a Strong Buy with an average price target of $32.20, representing an 825.3% upside. In a report issued on July 1, JMP Securities also maintained a Buy rating on the stock with a $24.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
KalVista Pharmaceuticals (KALV)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on KalVista Pharmaceuticals, with a price target of $48.00. The company’s shares closed last Friday at $11.07.
According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for KalVista Pharmaceuticals with a $39.33 average price target, which is a 267.9% upside from current levels. In a report issued on July 7, Needham also maintained a Buy rating on the stock with a $38.00 price target.
Oramed Pharmaceuticals (ORMP)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Friday at $8.20, close to its 52-week low of $3.59.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Oramed Pharmaceuticals is a Moderate Buy with an average price target of $31.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MGNX:
- Needham Thinks Taboola.com’s Stock is Going to Recover
- Fortuna reports solid production of 96,712 gold equivalent ounces for the second quarter of 2022
- Himax Technologies, Inc. Schedules Second Quarter 2022 Financial Results Conference Call on Thursday, August 11 at 8:00 AM EDT
- NIO Inc. Provides Update on Response to Short Seller Report
- New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A
